Monday, June 2, 2014
Jeffery Ward, an oncologist
at Swedish Cancer Institute and chair of the ASCO payment reform working
group, said the task force considered alternatives to buy-and-bill but couldn't
arrive at a solution.
He also said concerns that
buy-and-bill leads oncologists to favor expensive IV drugs are exaggerated.
Indeed, he said the ASP+6% method provides "an incentive to look for the